Xofigo-radium RA 223 dichloride INJ
Ended Awarded Last action
- Contract number
- 36C24825N0317
- Awardee
-
Bayer Healthcare Pharmaceuticals Inc. UEI V1EVGCK7XES8 Part of Bayer Aktiengesellschaft
- Awarding agency
-
Veterans Integrated Service Network 8
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $53,828
Award facts
- Contract value 100% obligated
- $53,828.41 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Whippany, Hanover, NJ 07981, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$177,936 | |
| Original award | $231,764 |
About this award
Bayer Healthcare Pharmaceuticals Inc. was awarded a delivery order valued at $53,828.41 for Xofigo (radium Ra 223 dichloride injection), a specialized radiopharmaceutical used to treat castration-resistant prostate cancer. The award was issued by Veterans Integrated Service Network 8 on January 15, 2025, with an ultimate completion date of January 14, 2026. This firm fixed-price delivery order was issued without a small business set-aside designation and will be performed in Whippany, New Jersey. The award is issued under Bayer Healthcare Pharmaceuticals Inc.'s $840 million multiple-award Federal Supply Schedule contract (FSS-61-IB) for Pharmaceuticals and Drugs with the Department of Veterans Affairs, which enables federal agencies to procure pharmaceutical products at pre-negotiated pricing.
Bayer Healthcare Pharmaceuticals Inc., a subsidiary of Germany-based Bayer AG, maintains an established role as a critical supplier of specialized pharmaceutical products to the federal healthcare system, with particular emphasis on radiopharmaceuticals and single-source medications essential to veteran healthcare programs. The company also holds a $6.8 million Blanket Purchase Agreement awarded by the Department of Veterans Affairs National Acquisition Center in October 2025, specifically covering Xofigo and related specialty medications, which streamlines procurement across authorized federal agencies. This delivery order supports the Veterans Health Administration's cancer treatment capabilities and reflects the recurring procurement patterns across multiple Veterans Integrated Service Networks for this essential oncology medication.
Quick answers
Who was awarded contract 36C24825N0317?
36C24825N0317 was awarded to Bayer Healthcare Pharmaceuticals Inc. by Veterans Integrated Service Network 8 (Veterans Health Administration) on January 15, 2025.
How much is contract 36C24825N0317 worth?
The government has obligated $53,828 on 36C24825N0317.
Is contract 36C24825N0317 an order under another contract?
Yes. 36C24825N0317 is a delivery order under 36F79720D0237, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24825N0317 competed?
The extent of competition for 36C24825N0317 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award